Cumberland Q3 2023: net loss $1.0M, revenue $10.1M, YTD adj. EPS $0.29

CUMBERLAND PHARMACEUTICALS INC

2024-Q3 EPS reported $0.00 revenue$30,199,441

Net loss of $1.0M; adjusted earnings $260K ($0.02/share); YTD net income $15K, adj. EPS $0.29.
Product revenue $10.1M (Kristalose $3.9M, Vibativ $2.8M, Sancuso $1.9M, Caldolor $1.2M).
New $25M revolving credit facility with Pinnacle Bank; $12.9M drawn at quarter-end.
Sancuso acquisition transition completed; FDA approved new mfg plant; supplies underway Q4 2023.
NOPAIN Act may provide separate Medicare reimbursement for Caldolor from 2025; ifetroban Phase II trials ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CUMBERLAND PHARMACEUTICALS INC reported financial results for the three and nine months ended September 30, 2023.

Period: the three and nine months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three and nine months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001628280-23-037446

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.